Multicentre controlled open randomised clinical trial to assess efficacy and safety of an anti-tuberculosis drug combination based on optimised-dose rifampicin, optimised-dose moxifloxacin and optimised-dose linezolid for TB: the RML-TB trial protocol.
Diab Casares L, Espinosa Pereiro J, Tórtola Fernández MT, Casas García X, Millet JP, Pomar Solchaga V, Navas Elorza E, Troya García J, Díaz de Santiago A, Luque Márquez R, Medina Gallardo JF, González Galán V, Montero Alonso M, Gil Brusola A, Rabuñal Rey R, Anibarro García L, Sanz Herrero F, Guna Serrano R, Garrigó Fullola M, Tato Díez M, Talavan Zanón T, Portero MF, Alonso García P, Saez López AM, Aznar ML, Martínez Campreciós J, Saborit N, Sánchez Montalvá A.
Diab Casares L, et al. Among authors: pomar solchaga v.
BMJ Open Respir Res. 2025 Dec 7;12(1):e002475. doi: 10.1136/bmjresp-2024-002475.
BMJ Open Respir Res. 2025.
PMID: 41360613
Free PMC article.